Discover undervalued stocks with Eulerpool.

Subscribe for $2

Acceleron Pharma Stock XLRN

Price

0
Today +/-
-0
Today %
-0 %

Acceleron Pharma stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Acceleron Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Acceleron Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Acceleron Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Acceleron Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Acceleron Pharma Stock Price History

DateAcceleron Pharma Price
11/22/20210 undefined
11/22/2021178.75 undefined
11/18/2021178.75 undefined

Acceleron Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Acceleron Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Acceleron Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Acceleron Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Acceleron Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Acceleron Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Acceleron Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Acceleron Pharma’s growth potential.

Acceleron Pharma Revenue, EBIT and net profit per share

DateAcceleron Pharma RevenueAcceleron Pharma EBITAcceleron Pharma Net Income
2025e642.76 M undefined0 undefined-203.71 M undefined
2024e436.36 M undefined0 undefined-159.77 M undefined
2023e302.16 M undefined0 undefined-127.82 M undefined
2022e215.16 M undefined0 undefined-204.43 M undefined
2021e139.56 M undefined0 undefined-247.87 M undefined
202092.52 M undefined-167.31 M undefined-166.03 M undefined
201973.99 M undefined-136.45 M undefined-124.86 M undefined
201813.99 M undefined-124.41 M undefined-118.87 M undefined
201713.48 M undefined-109.98 M undefined-108.45 M undefined
201627.77 M undefined-66.11 M undefined-57.01 M undefined
201518.1 M undefined-60.88 M undefined-63.89 M undefined
201414.63 M undefined-50.46 M undefined-51.26 M undefined
201357.23 M undefined6.95 M undefined-21.9 M undefined
201215.25 M undefined-28.89 M undefined-32.58 M undefined
201180.91 M undefined38.56 M undefined36.27 M undefined

Acceleron Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20112012201320142015201620172018201920202021e2022e2023e2024e2025e
80155714182713137392139215302436642
--81.25280.00-75.4428.5750.00-51.85-461.5426.0351.0954.6840.4744.3747.25
98.75100.0026.32107.1483.3355.56115.38115.3820.5516.3010.796.984.973.442.34
79150000000000000
36-32-21-51-63-57-108-118-124-166-247-204-127-159-203
--188.89-34.38142.8623.53-9.5289.479.265.0833.8748.80-17.41-37.7525.2027.67
2.722.49.4131.5233.337.4340.4245.952.4556.800000
- - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Acceleron Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Acceleron Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (k)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2011201220132014201520162017201820192020
                   
6539.6113.2176.5104.8139.7277.2291.3431.4849.9
11.83.63.43.63.23.678.526.1
7001,00000000000
0000000000
11.52.22.52.53.94.47.71017.3
67.743.9119182.4110.9146.8285.2306449.9893.3
4.94.13.73.13.15.277.130.729.8
000031.194.795.7022.57.6
20020000000000
0000000000
0000000000
0.91.110.91.211.21.71.81.7
65.44.7435.4100.9103.98.85539.1
73.749.3123.7186.4146.3247.7389.1314.8504.9932.4
                   
241.5268.60000000.10.1
000.250.40.420.590.840.881.161.73
-232.7-291-192.3-243.6-307.5-364.5-473-586.5-711.4-877.4
0000-0.2-0.4-0.9-0.60-0.3
0000000000
8.8-22.457.8156.2109.2225.6365.2292449.5855.2
1.90.60.90.70.91.61.10.42.38.5
4.56.26.96.811.212.513.817.630.149.2
11.428.32.51.72.421.90.912.5
63.716.90000000
0000000000
23.838.827.29.214.516.116.818.933.460.2
117.900000000
0000000000
4014.838.720.822.65.97.23.922.117.1
4132.738.720.822.65.97.23.922.117.1
64.871.565.93037.1222422.855.577.3
73.649.1123.7186.2146.3247.6389.2314.8505932.5
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Acceleron Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Acceleron Pharma's financial health and stability.

Assets

Acceleron Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Acceleron Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Acceleron Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Acceleron Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (k)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020
36-32-21-51-63-57-108-118-124-166
3101112333
0000000000
-32-11-28-2300-430
23290151129242331
1,0001,0001,0001,000000000
0000000000
9-38-19-53-44-44-76-94-93-130
00000-3-4-2-3-4
0000-108-108-64122-7125
0000-108-105-59125-6829
0000000000
-913-3-16000000
30097133414622017258538
211393117414622016258538
----------
0000000000
30-257363-148-6794493433
0000000000
0000000000

Acceleron Pharma stock margins

The Acceleron Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acceleron Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acceleron Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Acceleron Pharma's sales revenue. A higher gross margin percentage indicates that the Acceleron Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Acceleron Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Acceleron Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Acceleron Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Acceleron Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Acceleron Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Acceleron Pharma Margin History

Acceleron Pharma Gross marginAcceleron Pharma Profit marginAcceleron Pharma EBIT marginAcceleron Pharma Profit margin
2025e100 %0 %-31.69 %
2024e100 %0 %-36.62 %
2023e100 %0 %-42.3 %
2022e100 %0 %-95.02 %
2021e100 %0 %-177.61 %
2020100 %-180.84 %-179.45 %
2019100 %-184.42 %-168.75 %
2018100 %-889.28 %-849.68 %
2017100 %-815.88 %-804.53 %
2016100 %-238.06 %-205.29 %
2015100 %-336.35 %-352.98 %
2014100 %-344.91 %-350.38 %
2013100 %12.14 %-38.27 %
2012100 %-189.44 %-213.64 %
201198.15 %47.66 %44.83 %

Acceleron Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Acceleron Pharma earnings per share therefore indicates how much revenue Acceleron Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Acceleron Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Acceleron Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Acceleron Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Acceleron Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Acceleron Pharma Revenue, EBIT and net profit per share

DateAcceleron Pharma Sales per ShareAcceleron Pharma EBIT per shareAcceleron Pharma Earnings per Share
2025e10.65 undefined0 undefined-3.37 undefined
2024e7.23 undefined0 undefined-2.65 undefined
2023e5 undefined0 undefined-2.12 undefined
2022e3.56 undefined0 undefined-3.39 undefined
2021e2.31 undefined0 undefined-4.11 undefined
20201.63 undefined-2.95 undefined-2.92 undefined
20191.41 undefined-2.6 undefined-2.38 undefined
20180.3 undefined-2.71 undefined-2.59 undefined
20170.33 undefined-2.72 undefined-2.68 undefined
20160.74 undefined-1.77 undefined-1.52 undefined
20150.54 undefined-1.83 undefined-1.92 undefined
20140.46 undefined-1.6 undefined-1.63 undefined
20136.08 undefined0.74 undefined-2.33 undefined
20126.35 undefined-12.04 undefined-13.58 undefined
201129.75 undefined14.18 undefined13.33 undefined

Acceleron Pharma business model

Acceleron Pharma Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2003 by a group of scientists specializing in drug development in the fields of oncology and hematology. The company's business model is based on the discovery and development of innovative therapeutic solutions, particularly in the areas of oncology and rare diseases. They use a wide range of technologies to identify potential target molecules and test their effectiveness. Acceleron Pharma operates in three different business areas: oncology, hemoglobinopathies, and musculoskeletal diseases. In oncology, the company focuses on developing drugs to treat cancers such as multiple myeloma or pancreatic cancer. The hemoglobinopathies division of Acceleron Pharma develops therapies for patients with rare blood disorders such as beta-thalassemia and sickle cell disease. In the field of musculoskeletal diseases, the company is working on developing therapies for muscle, connective tissue, and joint disorders. One of Acceleron Pharma's key products is the drug Reblozyl, which was developed in collaboration with Bristol Myers Squibb. Reblozyl is the first FDA-approved medication for the treatment of anemia in patients with beta-thalassemia. The company has also entered into a partnership agreement with Celgene to develop medications for the treatment of inflammatory bowel diseases. Acceleron Pharma has also successfully partnered with other major pharmaceutical companies such as Pfizer and Sanofi in the past. Through these partnerships, the company has provided its technology platform for the discovery and development of drugs for various indications such as cancer and muscle diseases. Acceleron Pharma is a fast-growing company dedicated to researching and developing innovative therapies for rare diseases. With a wide range of technologies and a strong pipeline of clinical candidates, the company is well-equipped to treat patients affected by these rare diseases. Acceleron Pharma is one of the most popular companies on Eulerpool.com.

Acceleron Pharma SWOT Analysis

Strengths

1. Strong research and development capabilities in the biopharmaceutical industry.

2. Extensive pipeline of innovative therapies and drugs.

3. Well-established partnerships and collaborations with leading pharmaceutical companies.

4. Robust intellectual property portfolio protecting their products and technologies.

Weaknesses

1. Heavy reliance on a limited number of drug candidates in the pipeline.

2. Vulnerability to clinical trial failures and regulatory hurdles.

3. High research and development costs affecting profitability.

4. Limited market presence compared to larger pharmaceutical companies.

Opportunities

1. Increasing demand for innovative therapies and treatments in the healthcare industry.

2. Growing global market for biopharmaceutical products.

3. Potential for strategic partnerships and collaborations to expand market reach.

4. Advances in technology and genomics providing new avenues for research and development.

Threats

1. Intense competition from established pharmaceutical companies and emerging biotech firms.

2. Stringent regulatory requirements and lengthy approval processes.

3. Uncertainties surrounding healthcare policies and pricing pressures.

4. Potential risks associated with market volatility and economic fluctuations.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Acceleron Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Acceleron Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Acceleron Pharma shares outstanding

The number of shares was Acceleron Pharma in 2024 — This indicates how many shares 56.8 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Acceleron Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Acceleron Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Acceleron Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Acceleron Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Acceleron Pharma.

Acceleron Pharma shareholders

%
Name
Stocks
Change
Date
11.60734 % Celgene Corporation7,008,510183,8257/9/2020
8.88561 % T. Rowe Price Associates, Inc.5,365,13365,3219/30/2021
8.15699 % The Vanguard Group, Inc.4,925,18914,8369/30/2021
6.62471 % Avoro Capital Advisors LLC4,000,0001,000,0009/30/2021
3.94211 % BlackRock Institutional Trust Company, N.A.2,380,249-19,8359/30/2021
3.58507 % Farallon Capital Management, L.L.C.2,164,663-335,3379/30/2021
3.31236 % Darwin Global Management Ltd2,000,000239,6549/30/2021
3.24598 % Fidelity Management & Research Company LLC1,959,920-677,6789/30/2021
2.63887 % Janus Henderson Investors1,593,352-208,4709/30/2021
2.14143 % Baron Capital Management, Inc.1,292,998-9,2779/30/2021
1
2
3
4
5
...
10

Most common questions regarding Acceleron Pharma

What values and corporate philosophy does Acceleron Pharma represent?

Acceleron Pharma Inc represents values of innovation, collaboration, and patient-centricity. As a leading biopharmaceutical company, Acceleron is committed to developing transformative therapies for patients with serious and rare diseases. They prioritize scientific excellence and are dedicated to advancing research to improve patient outcomes. Acceleron's corporate philosophy revolves around discovering and delivering therapies that address unmet medical needs. With a focus on sustainable growth, they strive to create long-term value for their shareholders. By leveraging their expertise in biology and translational medicine, Acceleron Pharma Inc is driving advancements in the field of medicine to benefit patients worldwide.

In which countries and regions is Acceleron Pharma primarily present?

Acceleron Pharma Inc is primarily present in various countries and regions around the world. Some of the key markets where the company operates include the United States, Europe, and Asia. With its headquarters in Cambridge, Massachusetts, Acceleron Pharma Inc has established a significant presence in the pharmaceutical industry across these regions. Additionally, the company continues to expand its global footprint through strategic partnerships and collaborations. As a renowned pharmaceutical organization, Acceleron Pharma Inc's presence can be observed in numerous countries and regions, making it a prominent player in the international healthcare market.

What significant milestones has the company Acceleron Pharma achieved?

Acceleron Pharma Inc has achieved several significant milestones. One notable milestone is the FDA approval of their drug, REBLOZYL®, in November 2019. This approval marked a major breakthrough for Acceleron Pharma Inc, as REBLOZYL® became the first and only erythroid maturation agent approved for the treatment of anemia in patients with beta thalassemia. Additionally, Acceleron Pharma Inc also received FDA approval for REBLOZYL® in April 2020 for the treatment of anemia in adult patients with lower-risk myelodysplastic syndromes (MDS). These milestones demonstrate the company's dedication to developing innovative treatments and addressing unmet medical needs.

What is the history and background of the company Acceleron Pharma?

Acceleron Pharma Inc. is a biopharmaceutical company founded in 2003, headquartered in Cambridge, Massachusetts. The company specializes in the discovery, development, and commercialization of innovative therapies for patients with serious and rare diseases. Acceleron focuses on developing drugs that regulate the transforming growth factor-beta (TGF-beta) superfamily of proteins, which play a crucial role in various biological processes. Notably, the company's expertise lies in the field of protein therapeutics, including the engineering of molecules that enhance the body's natural processes. Acceleron Pharma Inc. has collaborated with major pharmaceutical companies to advance its pipeline of potential therapies. With its commitment to addressing unmet medical needs, Acceleron continues to make significant contributions to the pharmaceutical industry.

Who are the main competitors of Acceleron Pharma in the market?

The main competitors of Acceleron Pharma Inc in the market are Amgen Inc., Eli Lilly and Company, and Johnson & Johnson.

In which industries is Acceleron Pharma primarily active?

Acceleron Pharma Inc is primarily active in the biotechnology industry.

What is the business model of Acceleron Pharma?

The business model of Acceleron Pharma Inc revolves around the development and commercialization of novel therapies for patients with serious and rare diseases. Acceleron focuses on the discovery and development of protein therapeutics that target the TGF-beta superfamily of proteins. By leveraging its expertise in this therapeutic area, Acceleron aims to harness the potential of these proteins to address the underlying causes of various diseases. With an emphasis on research and development, Acceleron strives to bring innovative treatments to market, improving the lives of patients worldwide.

What is the P/E ratio of Acceleron Pharma 2025?

The P/E ratio cannot be calculated for Acceleron Pharma at the moment.

What is the P/S ratio of Acceleron Pharma 2025?

The P/S cannot be calculated for Acceleron Pharma currently.

What is the Quality Investing of Acceleron Pharma?

The Quality Investing for Acceleron Pharma is 3/10.

What is the revenue of Acceleron Pharma 2025?

The expected Acceleron Pharma revenue is 642.76 M USD.

How high is the profit of Acceleron Pharma 2025?

The expected Acceleron Pharma profit is -203.71 M USD.

What is the business model of Acceleron Pharma

Acceleron Pharma Inc is a biopharmaceutical company focused on the development of therapies for rare diseases. They have an innovative platform for the discovery and development of drugs based on growth and differentiation factors that have the potential to improve the lives of patients. The company has several partnerships with major pharmaceutical companies such as Celgene and Bristol-Myers Squibb to jointly develop and market their products. Acceleron Pharma focuses on researching diseases with high unmet medical needs, such as pulmonary arterial hypertension, hearing loss, and beta-thalassemia. One of Acceleron Pharma's main products is Luspatercept, a recombinant fusion protein consisting of two TGF-beta receptor II ectodomains and an IgG Fc portion. It has been developed to treat patients with beta-thalassemia and myelodysplastic syndromes. In clinical studies, Luspatercept has shown impressive results and has been approved in the US and Europe. Another product of Acceleron Pharma is Sotatercept, an investigational drug in clinical development for the treatment of pulmonary arterial hypertension (PAH) and chronic kidney disease (CKD). Sotatercept is a recombinant fusion protein consisting of the extracellular portion of the ACVR2B receptor and the Fc portion of human IgG1 antibody. It has the potential to stimulate the growth of blood vessels and bone cells, which can contribute to improving lung function and bone health. Acceleron Pharma also has a pipeline of products in clinical development aiming to treat a variety of diseases. The company is currently working on the development of therapies for hearing loss, systemic sclerosis, neuromuscular diseases, and hematological diseases. Overall, Acceleron Pharma pursues a business model based on the discovery and development of therapies for rare diseases. They collaborate closely with strategic partners to develop and market their products. With their focus on unmet medical needs and innovative drug research, they have the potential to improve the lives of patients and become a significant player in biopharmaceuticals.

What is the Acceleron Pharma dividend?

Acceleron Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does Acceleron Pharma pay dividends?

The dividend cannot currently be calculated for Acceleron Pharma or the company does not pay out a dividend.

What is the Acceleron Pharma ISIN?

The ISIN of Acceleron Pharma is US00434H1086.

What is the Acceleron Pharma WKN?

The WKN of Acceleron Pharma is A1W5LE.

What is the Acceleron Pharma ticker?

The ticker of Acceleron Pharma is XLRN.

How much dividend does Acceleron Pharma pay?

Over the past 12 months, Acceleron Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acceleron Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Acceleron Pharma?

The current dividend yield of Acceleron Pharma is .

When does Acceleron Pharma pay dividends?

Acceleron Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acceleron Pharma?

Acceleron Pharma paid dividends every year for the past 0 years.

What is the dividend of Acceleron Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acceleron Pharma located?

Acceleron Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acceleron Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acceleron Pharma from 10/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2025.

When did Acceleron Pharma pay the last dividend?

The last dividend was paid out on 10/4/2025.

What was the dividend of Acceleron Pharma in the year 2024?

In the year 2024, Acceleron Pharma distributed 0 USD as dividends.

In which currency does Acceleron Pharma pay out the dividend?

The dividends of Acceleron Pharma are distributed in USD.

All fundamentals about Acceleron Pharma

Our stock analysis for Acceleron Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acceleron Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.